Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 24;50(5):371-381.
doi: 10.1159/000529691. eCollection 2023 Oct.

Autologous Stem Cell Collection after Daratumumab, Bortezomib, Thalidomide, and Dexamethasone versus Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma

Sandra Sauer  1 , Katharina Kriegsmann  1 , Cathleen Nientiedt  2 , Anita Schmitt  1 , Carsten Müller-Tidow  1   2 , Marc-Steffen Raab  1   2 , Joseph Kauer  1   3
Affiliations

Autologous Stem Cell Collection after Daratumumab, Bortezomib, Thalidomide, and Dexamethasone versus Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma

Sandra Sauer et al. Transfus Med Hemother. .

Abstract

Introduction: In transplant-eligible, newly diagnosed multiple myeloma (NDMM) patients, autologous peripheral blood stem cell (PBSC) collection is usually pursued after induction therapy. While induction regimens are constantly refined regarding response, their impact on PBSC collection is not fully studied. The inclusion of the anti-CD38 antibody daratumumab into induction therapy significantly improved outcomes for patients with NDMM, e.g., as part of the daratumumab, bortezomib, thalidomide, and dexamethasone (Dara-VTD) protocol. Preliminary data from the phase 3 CASSIOPEIA study proved the efficacy of Dara-VTD. While overall PBSC collection upon addition of daratumumab was reduced in the study population, more detailed analyses on the impact are missing.

Methods: We here report on PBSC mobilization and collection metrics in n = 119 patients with NDMM who underwent induction therapy with bortezomib, cyclophosphamide, and dexamethasone (VCD, n = 61) or Dara-VTD (n = 58).

Results: Patient characteristics were well balanced between groups. The Dara-VTD group showed improved response parameters with 66% of patients reaching at least very good partial response versus 54% in the VCD group. Dara-VTD patients exhibited inferior mobilization metrics such as peripheral blood CD34+ cell count at the first leukapheresis (LP) session (65 vs. 106/μL, p = 0.001), median number of LP sessions (2 vs. 1, p = 0.001), and PBSC collection at first LP (5.5 vs. 8.3 × 106/kg body weight [bw], p = 0.001). Utilization of plerixafor was slightly higher after Dara-VTD (33% vs. 21% of patients, p = 0.143). The overall PBSC collection result was significantly lower after Dara-VTD (8.4 vs. 9.6 × 106/kg bw, p = 0.026). 78% and 85% of patients successfully collected 3 transplants with ≥2 × 106 CD34+ cells/kg bw in the Dara-VTD and the VCD groups, respectively.

Conclusion: In summary, Dara-VTD, possibly due to both anti-CD38 antibody and thalidomide exposure, imposes a limitation on PBSC collection which can be only partly overcome by utilization of plerixafor.

Keywords: Daratumumab; Leukapheresis; Multiple myeloma; Stem cell collection; Thalidomide.

PubMed Disclaimer

Conflict of interest statement

The first authors and all coauthors confirm that there are no potential conflicts of interest to disclose, except the following. Joseph Kauer: Honoraria: AstraZeneca. Sandra Sauer: travel grants or honoraria for presentations for Celgene, BMS, Janssen, Takeda, and Amgen. Katharina Kriegsmann: research funding and honoraria from Sanofi. A.S. received travel grants from Hexal and Jazz Pharmaceuticals, research grant from Therakos/Mallinckrodt, consultant by Janssen-Cilag and BMS, and is co-founder of TolerogenixX Ltd. A.S. is a part-time employee of TolerogenixX Ltd.

Figures

Fig. 1
Fig. 1
PBSC mobilization metrics. a Time difference (days) between planned and actual date of LP1. b PBSC collection (CD34+ cells ×106/kg bw) upon the LP1 session. c PB CD34+ cell count (/μL) after mobilization. d Number of LP sessions until collection goal (% of subgroup). e Percentage of patients reaching collection goal after respective LP.
Fig. 2
Fig. 2
PBSC collection results. a Plerixafor use due to poor mobilization (% of subgroup). b Plerixafor doses per 100 patients that underwent PBSC collection. c Ratio of PB CD34+ cell count after and before plerixafor application. d PBSC collection (CD34+ cells ×106/kg bw) without plerixafor versus after plerixafor. e Overall PBSC collection results (CD34+ cells ×106/kg bw). f Collection goal reached after all LP sessions (% of subgroups).
See this image and copyright information in PMC

References

    1. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med. 1996;335((2)):91–97. - PubMed
    1. Hübel K, de la Rubia J, Azar N, Corradini P. Current status of haematopoietic autologous stem cell transplantation in lymphoid malignancies a European perspective. Eur J Haematol. 2015;94((1)):12–22. - PubMed
    1. Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, et al. Lenalidomide and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376((14)):1311–1320. - PMC - PubMed
    1. Moreau P, San Miguel J, Sonneveld P, Mateos MV, Zamagni E, Avet-Loiseau H, et al. Multiple myeloma ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28((Suppl 4))(iv):52–61. - PubMed
    1. Chute JP. Autologous stem cell transplantation for multiple myeloma underutilized but highly effective. J Natl Cancer Inst. 2019;111((1)):7–8. - PubMed